Inorganic nanoparticle-based advanced cancer therapies: Promising combination strategies.
Cancer drug delivery
Cancer therapy
Combination therapy
Nanocarriers
Nanoparticle drug delivery
RNAi
siRNA drug delivery
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
22
12
2021
revised:
15
08
2022
accepted:
24
09
2022
pubmed:
2
10
2022
medline:
29
11
2022
entrez:
1
10
2022
Statut:
ppublish
Résumé
Inorganic nanoparticles for drug delivery in cancer treatment offer many potential advantages because they can maximize therapeutic effect through targeting ligands while minimizing off-target side-effects through drug adsorption and infiltration. Although inorganic nanoparticles were introduced as drug carriers, they have emerged as having the capacity for combined therapeutic capabilities, including anticancer effects through cytotoxicity, suppression of oncogenes and cancer cell signaling pathway inhibition. The most promising advanced strategies for cancer therapy are as synergistic platforms for RNA interference (siRNA, miRNA, shRNA) and as synergistic drug delivery agents for the inhibition of cancer cell signaling pathways. The present work summarizes relevant current work, the promise of which is suggested by a projected compound annual growth rate of ∼ 20% for drug delivery alone.
Identifiants
pubmed: 36182068
pii: S1359-6446(22)00379-8
doi: 10.1016/j.drudis.2022.103386
pii:
doi:
Substances chimiques
Drug Carriers
0
RNA, Small Interfering
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103386Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.